Cargando…

Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma

PURPOSE: In this study, we aimed to compare the radiation-induced hepatic toxicity (RIHT) outcomes of radiotherapy (RT) plus antibodies against programmed cell death protein 1 (anti-PD1) versus RT alone in patients with hepatocellular carcinoma (HCC), evaluate prognostic factors of non-classic radia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rui-Jun, Zhou, Hong-Mei, Lu, Hai-Yan, Yu, Hong-Ping, Tang, Wei-Zhong, Qiu, Mo-Qin, Yan, Liu-Ying, Long, Mei-Ying, Su, Ting-Shi, Xiang, Bang-De, He, Mei-Ling, Wang, Xiao-Ting, Liang, Shi-Xiong, Li, Jian-Xu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403970/ https://www.ncbi.nlm.nih.gov/pubmed/37542246 http://dx.doi.org/10.1186/s13014-023-02309-1

Ejemplares similares

Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
por: Li, Jian-Xu, et al.
Publicado: (2022)

Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma
por: Li, Jian-Xu, et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
por: Li, Jian-Xu, et al.
Publicado: (2022)

Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
por: Li, Jian-Xu, et al.
Publicado: (2022)

Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion
por: Su, Ting-Shi, et al.
Publicado: (2020)

Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma
por: Chen, Hai-yan, et al.
Publicado: (2013)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities
por: HUANG, BING-SHEN, et al.
Publicado: (2013)

No Association between TGFB1 Polymorphisms and Late Radiotherapy Toxicity: A Meta-Analysis
por: Zhu, Mei-Ling, et al.
Publicado: (2013)

Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
por: Su, Ting-Shi, et al.
Publicado: (2021)

Irradiation stability and cytotoxicity of gold nanoparticles for radiotherapy
por: Zhang, Xiao-Dong, et al.
Publicado: (2009)

Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy
por: Song, Jin Ho, et al.
Publicado: (2017)

Comparison of three‐dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus
por: Su, Fang, et al.
Publicado: (2018)

Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma
por: Chen, Hai-yan, et al.
Publicado: (2014)

Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy
por: Ye, Lu‐Lu, et al.
Publicado: (2019)

Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma
por: Zhong, Jian-Hong, et al.
Publicado: (2015)

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women
por: Wang, Weiping, et al.
Publicado: (2017)

Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study
por: Wu, Jun-Xin, et al.
Publicado: (2016)

Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol
por: Wang, Kang, et al.
Publicado: (2022)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma
por: Wei, Li-Chun, et al.
Publicado: (2013)

A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer
por: Lee, Kyong Joo, et al.
Publicado: (2016)

Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy
por: Zhao, Mei-Jun, et al.
Publicado: (2016)

Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2017)

Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis
por: Wang, Chun, et al.
Publicado: (2019)

Radiomics for Diagnosis and Radiotherapy of Nasopharyngeal Carcinoma
por: Zhang, Yu-mei, et al.
Publicado: (2022)

Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study
por: Zhang, Bin, et al.
Publicado: (2016)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Advances in radiotherapy and immunity in hepatocellular carcinoma
por: Yang, Yuhan, et al.
Publicado: (2023)

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
por: Duan, Yanan, et al.
Publicado: (2023)

Radiotherapy for Adult Medulloblastoma: Evaluation of Helical Tomotherapy, Volumetric Intensity Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy and the Results of Helical Tomotherapy Therapy
por: Zong-wen, Sun, et al.
Publicado: (2018)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Compared with intensity‐modulated radiotherapy, image‐guided radiotherapy reduces severity of acute radiation‐induced skin toxicity during radiotherapy in patients with breast cancer
por: Lin, Jang‐Chun, et al.
Publicado: (2018)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Laryngeal contact granuloma after radiotherapy in patients with nasopharyngeal carcinoma: a case series
por: Mo, Ting-Ting, et al.
Publicado: (2023)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023)

Analysis of simultaneous modulated accelerated radiotherapy (SMART) for nasopharyngeal carcinomas
por: Tang, Jian Min, et al.
Publicado: (2014)

Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma
por: Hsiang, Chih-Weim, et al.
Publicado: (2021)

Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
por: Du, Cheng-run, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9fki6t910h7lcnn1g8gg8cnmo6